Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Date:8/8/2008

share, compared with a net loss for the second quarter of 2007 of $4.8

million, or $0.07 per share. Net loss for the six months ended June

30, 2008 was $21.0 million, or $0.27 per share, compared with a net

loss of $8.2 million, or $0.11 per share, for the comparable period

last year.

-- Revenues for the second quarter of 2008 were $1.4 million, compared

with $709,000 for the second quarter of 2007. Revenues under

collaborative agreements for the second quarter of 2008 were $1.4

million, compared with $539,000 for the second quarter of 2007.

Revenues under collaborative agreements in 2008 primarily consisted of

the amortization of upfront fees received from Baxter and Roche of

$588,000 and research and development reimbursements from Baxter of

$554,000 and Roche of $210,000. Cumulase(R) product sales for the

second quarter of 2008 were $48,000, compared with $139,000 for the

second quarter of 2007.

-- Research and development expenses for the second quarter of 2008 were

$8.9 million, compared with $4.1 million for the second quarter of

2007, reflecting increased compensation expenses including share-based

compensation expenses, research and development spending on the

Company's Insulin, Bisphosphonates, and PEG PH20 clinical and

pre-clinical programs, and production costs associated with the

manufacturing scale-up of the Company's rHuPH20 enzyme.

-- Selling, general and administrative expenses for the second quarter of

2008 were $3.8 million, compared with $2.4 million for the second

quarter of 2007, reflecting increases in compensation expenses

including share-based compensation expenses, as well as higher legal

and facilities expenses compared with the prior-year quarter.

-- Cash and cash equivalents were $82.4 million as of Jun
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce ... PTI Inspection Systems that will enable it ... art leak testing method development and validation programs using ... As part of this agreement, Whitehouse Labs has taken ... Instrument developed and manufactured by PTI. The HVLD ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 /PRNewswire/ ... research report is available in its catalogue: ... 2014-2018 http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... materials are materials that are readily decomposed ... differs from conventional non-degradable packaging in terms ...
(Date:8/27/2014)... -- Research and Markets  has announced the ... Polymer, Food & Beverage, Personal Care & Pharmaceutical) ... report to their offering. Lactic acid ... carbon atom. The main applications of lactic acid ... personal care product, and pharmaceutical industries. Lactic ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014 ... The Graphene Opportunity - A Rational ... Is Graphene The New Nanotech? A similar ... predictions of applications ranging from microelectronics to water ... today announced the availability of the Graphene Opportunity ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... Wis. - Lucigen Corp . and ... giving Lucigen exclusive worldwide rights to manufacture and sell ... , ,Under the agreement, Imaxio will retain the right ... applications, but Lucigen will provide the cells to commercial ...
... - It has yet to turn a profit, and it ... scope, but the decision by Madison research tool manufacturer NimbleGen ... to $75 million is the latest bit of evidence that the ... continues a pattern of growth and visibility for NimbleGen, which ...
... Alfalight , a manufacturer of high-power diode lasers, has ... million from the U.S. Army Research Laboratory . ... suitable for pumping high-power, fiber-laser systems, developed in conjunction ... commercial products. , ,Manoj Kanskar, vice president of research ...
Cached Biology Technology:Lucigen Corp. enters global licensing agreement 2IPO-bound NimbleGen traveling in fast company 2IPO-bound NimbleGen traveling in fast company 3IPO-bound NimbleGen traveling in fast company 4
(Date:8/28/2014)... kilometres of new roads will be built worldwide by ... last wildernesses, where they bring an influx of destructive ... ambitious study has created a ,global roadmap, for prioritising ... the competing demands of development and environmental protection. , ... estimates that natural importance of ecosystems and a ,road-benefits, ...
(Date:8/28/2014)... alert the world to Global Warming, has called for ... underground. He says that Carbon Capture, combined with limits ... avoid global warming getting out of control over the ... made the call during his presentation to the International ... meeting to discuss Carbon Capture and Storage. , ...
(Date:8/28/2014)... Biologists at Ludwig-Maximilians-Universitaet (LMU) in Munich have assigned ... genus of predatory arthropods. These animals lived in ... than related forms found in Jurassic strata. ... their shallow marine habitat and were fossilized some ... other denizens of the Silurian seas although ...
Breaking Biology News(10 mins):Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2Paleontology: Oldest representative of a weird arthropod group 2
... lung cancer patients most likely to respond to the drug ... drug cetuximab (Erbitux), according to a new study published in ... National Cancer Institute. Both drugs target the same gene ... lung cancer (NSCLC) have mutant versions of the epidermal growth ...
... by manipulating energy regulation of cells, a collaborative study ... cells lacking a tumor-suppressing kinase called LKB1 can still ... This energy regulation is essential for keeping cells ... signal new advances for combating cancerous tumor growth, but ...
... Investigators report safety findings and statistically significant improvements ... 19th Annual Symposia on the Etiology, Pathogenesis and ... Phase I trial showed positive interim results in ... treatment, patients exhibited a statistically significant improvement in ...
Cached Biology News:Treatments have same target, different responses for lung cancer patients with genetic mutation 2Energy management in cells may hold key to cancer defense 2Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 2Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 3Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 4Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 5Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 6
ANTI S. GROUP AG:H...
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
... This service is for when you need to ... increase their transformation efficiency. Our services for preparing ... your applications. MCLab's custom competent cell service offers: ... ) Fast turnaround Quality ...
Biology Products: